Tokyo extended its gain for a second week, following mixed moves in the review week to February 9. The Nikkei 225 rose 1.2%, although it still finished below the psychologically-important 8,000 mark, while the Topix index inched up 0.1%. The market was strong mid-week, reflecting Japanese investors' purchasing of machinery, shipbuilding and steel stocks in anticipation of a recovery in the Chinese economy. The last two sessions saw a downturn due to profit-taking of the China-related issues and players resumed focusing on Japanese companies' dismal third-quarter earnings and increasingly uncertain outlook for the full year to March 2009. The pharmaceutical index lost 3.0%, underperforming the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze